Leech Therapy for Knee Osteoarthritis — The Landmark RCT

First RCT showing leech therapy superior to topical diclofenac for OA pain

Clinical TrialsMichalsen et al. (2003)— Annals of Internal MedicineDOI →

Why this matters for hirudotherapy

The strongest clinical evidence for hirudotherapy efficacy. Published in a top-tier internal medicine journal, this RCT established leech therapy as a viable treatment for osteoarthritis and set the methodological standard for subsequent trials.

Clinical Evidence — Not FDA-Evaluated

Uso investigacional. La terapia con sanguijuelas para osteoartritis no está autorizada por la FDA. Esta revisión resume la evidencia de ensayos clínicos con fines educativos.

Last Updated: March 5, 2026Reviewed by: Andrei Dokukin, MD

Antecedentes y significancia

Before 2003, evidence for leech therapy in osteoarthritis was limited to case reports and traditional practice accounts spanning centuries. Michalsen et al. conducted the first rigorous randomized controlled trial, published in the Annals of Internal Medicine — one of the highest-impact general medical journals. This established leech therapy as a subject worthy of serious clinical investigation.[R1]

Diseño del estudio

Intervention

Single application of 4–6 Hirudo medicinalis to the affected knee. Leeches were applied around the joint line and allowed to feed until spontaneous detachment (typically 30–60 minutes).

Control

Topical diclofenac gel (standard NSAID comparator) applied daily for 28 days. This was an active comparator design, making the results more clinically meaningful than placebo-controlled studies.

N = 51

Randomized patients

Knee OA

Symptomatic, confirmed

3–6 mo

Follow-up period

Data from Michalsen et al. (2003).[R1]

Resultados primarios

The leech therapy group demonstrated statistically significant and clinically meaningful improvements across all primary outcome measures:

Measure	Baseline	Day 28	Change
WOMAC total	52.3 ± 14	27.1 ± 18	−48%
WOMAC pain	11.2 ± 3.5	5.0 ± 4.0	−55%
VAS pain (0–100)	53.5	19.3	−35 mm
Physical function	31.6 ± 10	17.2 ± 13	−46%

All comparisons p < 0.001 vs baseline. Leech group superior to diclofenac at all time points.[R1]

Duración del efecto

One of the most remarkable findings was the duration of therapeutic effect from a single application. Pain relief was evident within 3 days, peaked at 28 days, and remained clinically significant at 3–6 month follow-up. This prolonged effect from one treatment session suggests mechanisms beyond simple anticoagulation — likely involving sustained anti-inflammatory activity, local tissue remodeling, and possible modulation of pain signaling pathways.[R1]

Perfil de seguridad

Adverse events in the leech group were limited to expected local effects: mild bleeding at application sites (self-limiting within 24 hours), local pruritus (itching) lasting 2–3 days, and small ecchymoses. No serious adverse events, no infections, and no systemic complications were reported. The safety profile compared favorably to the diclofenac group, which reported gastrointestinal discomfort in several patients.[R1]

Ensayos confirmatorios posteriores

The Michalsen 2003 study catalyzed a series of subsequent RCTs that broadly confirmed the initial findings:

Study	N	Design	Result
Andereya et al. 2006	113	Sham-controlled (knee OA)	Significant pain reduction vs sham
Lauche et al. 2014	4 RCTs	Meta-analysis	Pooled therapeutic benefit confirmed

Mecanismos propuestos

The prolonged effect of a single leech application suggests multiple overlapping mechanisms:

Anti-inflammatory

Leech saliva contains multiple anti-inflammatory compounds (bdellins, eglins, hyaluronidase) that may reduce joint inflammation and synovial fluid viscosity.

Microcirculatory

Local blood flow improvement through anticoagulant and vasodilatory effects may reduce tissue hypoxia and promote healing in the peri-articular tissues.

Analgesic

Direct analgesic compounds in leech SGS (including antistasins and possible opioid-like peptides) may modulate pain signaling at the peripheral level.

Counter-irritant

The bite itself may activate descending pain inhibition pathways (diffuse noxious inhibitory control), similar to acupuncture mechanisms.

Regulatory status

La terapia con sanguijuelas para osteoartritis no está autorizada por la FDA. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita al alivio de la congestión venosa en procedimientos microquirúrgicos. El uso para OA se considera investigacional/uso no indicado en los Estados Unidos. Las decisiones clínicas deben tomarse dentro de los marcos institucionales y regulatorios apropiados.

References

[R1]
Effectiveness of Leech Therapy in Osteoarthritis of the Knee: A Randomized, Controlled Trial
Annals of Internal Medicine(2003)https://doi.org/10.7326/0003-4819-139-9-200311040-00006
Primary source. First randomized controlled trial of leech therapy for OA.
[R2]
Effectiveness of Leech Therapy in Chronic Lateral Epicondylitis: A Randomized Controlled Trial
Clinical Journal of Pain(2014)https://doi.org/10.1097/AJP.0000000000000067
Subsequent Michalsen RCT extending leech therapy to musculoskeletal conditions.
[R3]
Leeches for Osteoarthritis of the Knee: A Systematic Review and Meta-Analysis
International Journal of Rheumatic Diseases(2014)https://doi.org/10.1111/1756-185X.12375
Lauche et al. meta-analysis of 4 RCTs confirming positive pooled effect.

← All research articles

Added to ASH library: February 27, 2026 | Site last updated: March 14, 2026